AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

Early TNBC Efficacy Signs From Datopotamab Deruxtecan

 
• By Alaric DeArment
  
Doctor with Mammography - Image
AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan shows early efficacy in triple-negative breast cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D